It looks like you're using an Ad Blocker.
Please white-list or disable AboveTopSecret.com in your ad-blocking tool.
Some features of ATS will be disabled while you continue to use an ad-blocker.
Originally posted by The Big O
I think its just as likely that it was contracted by a straight person who got it from an animal who then gave it to a gay person person.
Your "thousands of naked gay people orgy" thing is a bit much.
[edit on 11-3-2005 by The Big O]
Originally posted by Corgidancer
Finally, it doesn't matter if your part of the other 90% of whites, mixed, asian, indian, arab, black, yellow, just freeeeekin don't do drugs, shoot up drugs, share needles, engage in gay orgies with gays, do orgies with groups of strangers, and you will never get AIDS/HIV/!!! You don't need some special gene to protect from AIDS/HIV, you need to use common sense LOL!
Just because you don't do any of these things, doesn't save you if your partner has ever done them or might try them sometime.
This may not sound exciting, but delta 32 is a powerful mistake. HIV, the virus that causes AIDS, attacks the human immune system, infecting the white blood cells sent to destroy it. The delta 32 mutation, however, effectively blocks the crucial gateway into human cells the virus needs. In the case of Steve Crohn, whose partner was the fifth person to die from AIDS, possessing the CCR5 mutation has prevented him from contracting the virus.
O'Brien explains further, "In order to have total resistance to HIV, you have to carry two doses of the mutated gene -- one from each parent. If you get only one dose, you will not be resistant to infection. However, you may be able to delay the onset of HIV once you become infected. That's because, in patients with one copy of the mutation, the amount of 'portals' or 'doorways' that HIV can use is reduced by about 50 percent. That slows down virus replication, which is the most important factor in AIDS progression."
Scientists studying HIV first learned about the gateway-blocking capacity of the CCR5 mutation in 1996. Several drug companies, then, quickly began exploring the possibility of developing pharmaceuticals that would mimic delta 32 by binding to CCR5 and blocking the attachment of HIV. Previous methods of treatment interfered with HIV's ability to replicate after the virus has already entered a cell. This new class of HIV treatment, called early-inhibitor -- or fusion-inhibitor -- drugs seek to prevent the virus from ever attaching at all. These pharmaceuticals are still in relatively early stages of development, but certainly stand as a hopeful new method of approaching HIV treatment.